GPP
MCRB icon

Great Point Partners’s Seres Therapeutics MCRB Stock Holding History

Great Point Partners’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-13,750
Closed -$4.41M – 43
2017
Q3 		$4.41M Buy
+13,750
New +$3.76M 0.86% 28
2016
Q4 		– Sell
-6,000
Closed -$1.48M – 38
2016
Q3 		$1.48M Hold
6,000
– – 0.38% 30
2016
Q2 		$3.49M Buy
+6,000
New +$3.52M 1% 25

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Great Point Partners's MCRB Position: Q3 2023 in Review

Great Point Partners sold out of Seres Therapeutics (MCRB) in Q3 2023, closing a stake of 46,903 shares — an estimated $4.49M sold.

Great Point Partners first reported a position in MCRB in Q3 2016 and held it in 2 quarters. The position peaked at $4.49M in Q2 2023. 134 funds tracked by Wall St. Rank hold MCRB as of Q3 2023.

  • Great Point Partners reported no remaining Seres Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Great Point Partners sold 46,903 Seres Therapeutics shares in Q3 2023, an estimated $4.49M.
  • Great Point Partners first reported a position in Seres Therapeutics in Q3 2016 and held it in 2 quarters.
  • Great Point Partners's Seres Therapeutics position peaked at $4.49M in Q2 2023.
  • 134 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2023.

Based on Great Point Partners's 13F filing for Q3 2023, filed 14 Nov 2023.